FDA grants orphan drug designation for TLX102
Filed with ASX · · 2 pages · English
Watch Telix Pharmaceuticals' latest callTelix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings Call · Replay · Aug 20Read the transcript of Telix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings CallTelix Pharmaceuticals Limited on 6ix
Story so far
Earlier from Telix Pharmaceuticals
- Report for half-year to 30 June 2020
- Appendix 4C and Activities Report - June 2020 quarter
- Receipt of $11.4M R&D tax rebate
- FDA grants breakthrough designation for TLX250-CDx product
- S&P DJI Announces June 2020 Quarterly Rebalance
Later from Telix Pharmaceuticals
- IRE Distribution Partnership for Prostate Cancer Imaging
- Strategic Collaboration with Varian for Prostate Imaging
- Telix submits NDA to US FDA for Prostate Cancer Imaging
- FDA grants Orphan Drug Designation for glioma imaging agent
- App 4C and Activities Report for September 2020 Quarter
Follow Telix Pharmaceuticals into a list and get an email when it puts out news.
Follow Telix Pharmaceuticals